Healthcare Market News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 146,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "ec2003ca-5016-4ec4-a6e5-d75d11be646e",
"title": "Molina Healthcare Stock: Investor's Eye 2026 Repricing, Amid Ongoing Buybacks (NYSE:MOH)",
"description": "Molina Healthcare may rebound after 2025, with profitability driven by sector premium hikes. See here for MOH's potential 80%+ upside and buyback benefits.",
"keywords": "",
"snippet": "2025 marks an abysmal year for health insurance stocks, as higher-than-expected utilisation and medical costs lead to multiple profit warnings. Across the secto...",
"url": "https://seekingalpha.com/article/4850560-molina-healthcare-investors-eye-2026-repricing-amid-ongoing-buybacks",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160874775/image_2160874775.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2025-12-05T05:08:29.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "MOH",
"name": "Molina Healthcare, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 95.34339,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Molina</em> <em>Healthcare</em> Stock: Investor's Eye 2026 Repricing, Amid Ongoing Buybacks (<em>NYSE:MOH</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "b735db02-7e6a-433e-a8d7-d2e9771e0272",
"title": "Biocon among 6 F&O stocks saw a high increase in futures open interest - Futures Surge",
"description": "There was a notable surge in futures open interest for six stocks in the NSE F&O pack, contributing to a total increase in open interest of over 5% on December 4 as compared to the previous trade. A significant uptick in futures open interest signifies a substantial growth in the number of active, unexpired futures contracts in a specific security. This uptrend reflects an increasing number of participants either initiating new positions or expanding the size of their existing positions within the futures market. Futures Surge",
"keywords": "F&O open interest surge, Biocon futures OI, NSE derivatives data, fresh positions build-up, high OI stocks, futures market activity, open interest analysis, stock derivatives trends",
"snippet": "There was a notable surge in futures open interest for six stocks in the NSE F&O pack, contributing to a total increase in open interest of over 5% on December ...",
"url": "https://economictimes.indiatimes.com/markets/stocks/news/biocon-among-6-fo-stocks-saw-a-high-increase-in-futures-open-interest/slideshow/125780708.cms",
"image_url": "https://img.etimg.com/thumb/msid-125780708,width-1070,height-580,overlay-etmarkets/slideshow.jpg",
"language": "en",
"published_at": "2025-12-05T04:30:56.000000Z",
"source": "economictimes.indiatimes.com",
"relevance_score": null,
"entities": [
{
"symbol": "BIOCON.NS",
"name": "Biocon Limited",
"exchange": null,
"exchange_long": null,
"country": "in",
"type": "equity",
"industry": "Healthcare",
"match_score": 40.91779,
"sentiment_score": 0.6486,
"highlights": [
{
"highlight": "<em>Biocon</em> among 6 F&O stocks saw a high increase in futures open interest - Futures Surge",
"sentiment": 0.6486,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "7400220b-fe23-463f-ad16-8b9023b3aa26",
"title": "Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed",
"description": "Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.",
"keywords": "Healthcare, Biotech Stocks, ResMed, after hours, Vanda Pharmaceuticals, Cue Biopharma, Praxis Precision Medicines, Sensei Biotherapeutics, CooperCompanies",
"snippet": "Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory develo...",
"url": "https://www.rttnews.com/3601294/healthcare-biotech-stocks-rally-after-hours-sensei-praxis-cooper-vanda-cue-resmed.aspx?type=ts",
"image_url": "https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png",
"language": "en",
"published_at": "2025-12-05T04:23:49.000000Z",
"source": "rttnews.com",
"relevance_score": null,
"entities": [
{
"symbol": "RMD",
"name": "ResMed Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.499866,
"sentiment_score": 0.11315,
"highlights": [
{
"highlight": "<em>ResMed</em> <em>Inc</em>. (RMD) adde[+291 characters]",
"sentiment": 0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, <em>ResMed</em>",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "RSMDF",
"name": "ResMed Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.497498,
"sentiment_score": 0.11315,
"highlights": [
{
"highlight": "<em>ResMed</em> <em>Inc</em>. (RMD) adde[+291 characters]",
"sentiment": 0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, <em>ResMed</em>",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "CUE",
"name": "Cue Biopharma, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 44.061737,
"sentiment_score": -0.4019,
"highlights": [
{
"highlight": "<em>Cue</em> <em>Biopharma</em>, <em>Inc[+321 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "VNDA",
"name": "Vanda Pharmaceuticals Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 38.93335,
"sentiment_score": -0.25,
"highlights": [
{
"highlight": "<em>Vanda</em> <em>Pharmaceuticals</em> [+322 characters]",
"sentiment": -0.25,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "SNSE",
"name": "Sensei Biotherapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 44.22135,
"sentiment_score": -0.4837,
"highlights": [
{
"highlight": "<em>Sensei</em> <em>Biotherapeutics</em>[+282 characters]",
"sentiment": -0.4837,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "ff7c35f2-7949-40ae-a643-2779dfb0aedc",
"title": "Protara Announces Pricing of $75 Million Public Offering",
"description": "NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) ('Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underwritten public offering of 13,043,479 shares of its common stock at a price to the public of $5.75 per share. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 1,956,521 shares of common stock at the public offering price, less underwriting discounts and commissions. All shares in the offering are being sold by Protara. The gross proceeds from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and offering expenses payable by Protara and excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on December 8, 2025, subject to satisfaction of customary closing conditions. Protara intends to use the net proceeds received from the offering to fund the clinical development of TARA-002, as well as the development of other clinical programs. Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.",
"keywords": "Protara, Announces, Pricing, of, $75, Million, Public, Offering",
"snippet": "NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (\"Protara”), a clinical-stage company developing transformative therapie...",
"url": "https://www.manilatimes.net/2025/12/05/tmt-newswire/globenewswire/protara-announces-pricing-of-75-million-public-offering/2237631",
"image_url": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/05/855664.png",
"language": "en",
"published_at": "2025-12-05T03:18:21.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "TARA",
"name": "Protara Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 52.031937,
"sentiment_score": -0.083333,
"highlights": [
{
"highlight": "NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE)[+57 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>Nasdaq</em>: <em>TARA</em>) (\"Prota[+265 characters]",
"sentiment": -0.25,
"highlighted_in": "main_text"
},
{
"highlight": "Company Contact:\n\nAdvertisement\n\nJustine[+97 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "750959b0-53aa-4893-b10c-7b3e5ff7d18e",
"title": "The Cooper Companies, Inc. (COO) Q4 2025 Earnings Call Transcript",
"description": "The Cooper Companies, Inc. (COO) Q4 2025 Earnings Call December 4, 2025 5:00 PM ESTCompany ParticipantsKim Duncan - Vice President of Investor Relations...",
"keywords": "",
"snippet": "Presentation\n\nI would now like to turn the conference over to Kim Duncan, VP of Investor Relations and Risk Management. You may begin.\n\nLadies and gentlemen, th...",
"url": "https://seekingalpha.com/article/4850520-the-cooper-companies-inc-coo-q4-2025-earnings-call-transcript",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2025-12-05T02:58:49.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "COO",
"name": "The Cooper Companies, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 141.94696,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>The</em> <em>Cooper</em> <em>Companies</em>, <em>Inc</em>. (COO) Q4 2025 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "C1OO34.SA",
"name": "The Cooper Companies, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 141.94525,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>The</em> <em>Cooper</em> <em>Companies</em>, <em>Inc</em>. (COO) Q4 2025 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "89e5ff70-d24e-4d34-ba0b-b6002750c474",
"title": "Pfizer Inc. (PFE): A Bull Case Theory",
"description": "We came across a bullish thesis on Pfizer Inc. on HatedMoats’s Substack. In this article, we will summarize the bulls’ thesis on PFE.",
"keywords": "",
"snippet": "Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!\n\nAI i...",
"url": "https://www.insidermonkey.com/blog/pfizer-inc-pfe-a-bull-case-theory-3-1635918/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2021/11/06231044/spencer-davis-s4_g2TCyNHM-unsplash.jpg",
"language": "en",
"published_at": "2025-12-05T02:48:10.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFE",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 80.53958,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Pfizer</em> <em>Inc</em>. (PFE): A Bull Case Theory",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "PFE.SN",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 80.53711,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Pfizer</em> <em>Inc</em>. (PFE): A Bull Case Theory",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "1ec60b46-ae72-4d73-b4d9-ad1806d29725",
"title": "Bioventus Inc. (BVS) Presents at Piper Sandler 37th Annual Healthcare Conference - Slideshow (NASDAQ:BVS) 2025-12-04",
"description": "2025-12-04. The following slide deck was published by Bioventus Inc.",
"keywords": "",
"snippet": "To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.\n\nIf you have an ad-blocker enabled you may be blocked from ...",
"url": "https://seekingalpha.com/article/4850536-bioventus-inc-bvs-presents-at-piper-sandler-37th-annual-healthcare-conference-slideshow",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2025-12-05T01:32:24.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "BVS",
"name": "Bioventus Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 118.97182,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Bioventus</em> <em>Inc</em>. (BVS) Presents at Piper Sandler 37th Annual Healthcare Conference - Slideshow (<em>NASDAQ:BVS</em>) 2025-12-04",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "99c3f455-68ba-4920-b6c0-b76f8584de60",
"title": "世界の非動物代替検査市場の成長予測と未来展望（2031年価値とCAGR 13.5%）",
"description": "",
"keywords": "世界の非動物代替検査市場の成長予測と未来展望（2031年価値とCAGR 13.5%）, Panorama Data Insights Ltd., プレスリリース, ニュースリリース, 配信, 代行, DreamNews, ドリームニュース",
"snippet": "非動物代替実験技術は、動物実験を必要とせずに実験を実施するための革新的な方法として、医薬品開発、化学物質の?...",
"url": "https://www.dreamnews.jp/press/0000336164/",
"image_url": "https://www.dreamnews.jp//?action_Image=1&p=0000336164&id=bodyimage1",
"language": "ja",
"published_at": "2025-12-05T01:30:00.000000Z",
"source": "dreamnews.jp",
"relevance_score": null,
"entities": [
{
"symbol": "EVOTF",
"name": "Evotec SE",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.732948,
"sentiment_score": null,
"highlights": [
{
"highlight": ".● <em>Evotec</em> <em>SE</em>● Hure[+829 characters]",
"sentiment": null,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BIO",
"name": "Bio-Rad Laboratories, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 20.681183,
"sentiment_score": null,
"highlights": [
{
"highlight": ".● <em>Bio</em>-<em>Rad</em> <em>Labor[+704 characters]",
"sentiment": 0.0516,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BIO-B",
"name": "Bio-Rad Laboratories, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 20.681175,
"sentiment_score": null,
"highlights": [
{
"highlight": ".● <em>Bio</em>-<em>Rad</em> <em>Labor[+704 characters]",
"sentiment": 0.0516,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "EVTCY",
"name": "Evotec SE",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.731815,
"sentiment_score": null,
"highlights": [
{
"highlight": ".● <em>Evotec</em> <em>SE</em>● Hure[+829 characters]",
"sentiment": null,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "b9be6199-e550-42cd-8188-735d6ca71b8e",
"title": "India can build a $1.2-trillion bioeconomy by 2047",
"description": "Promoting innovation through capital-market innovation and regulatory modernisation, like China did, is the way to go",
"keywords": "Bioeconomy, Biotech, Research, Listing, China",
"snippet": "India’s bioeconomy has expanded 16-fold over the past decade — from $10 billion in 2014 to over $165 billion in 2024. With the right policy architecture, it...",
"url": "https://www.thehindubusinessline.com/opinion/india-can-build-a-12-trillion-bioeconomy-by-2047/article70358533.ece",
"image_url": "https://bl-i.thgim.com/public/incoming/tmqn44/article70358542.ece/alternates/LANDSCAPE_1200/BL05_Think_Biotech.jpg",
"language": "en",
"published_at": "2025-12-05T00:30:00.000000Z",
"source": "thehindubusinessline.com",
"relevance_score": null,
"entities": [
{
"symbol": "BIOCON.NS",
"name": "Biocon Limited",
"exchange": null,
"exchange_long": null,
"country": "in",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.330091,
"sentiment_score": 0,
"highlights": [
{
"highlight": "The writer is Chairperson, <em>Biocon</e[+39 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BIOCON.BO",
"name": "Biocon Limited",
"exchange": null,
"exchange_long": null,
"country": "in",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.02391,
"sentiment_score": 0,
"highlights": [
{
"highlight": "The writer is Chairperson, <em>Biocon</e[+39 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "6276d4e8-fff6-430d-9462-be5679eb95a2",
"title": "Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA",
"description": "ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct a global registrational Phase III study (POLARIS-1; NCT06051409) of its compound under investigation, olverembatinib, in combination with chemotherapy for the treatment of newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). As the second global registrational Phase III study of olverembatinib that has been cleared by regulators in the US and Europe, the POLARIS-1 study is simultaneously enrolling patients across trial centers in multiple countries in order to accelerate olverembatinib’s path to registration worldwide, particularly in the US and European markets.",
"keywords": "Ascentage, Pharma, Announces, Global, Registrational, Phase, III, Study, of, Olverembatinib, in, First-Line, Treatment, of, Ph+, ALL, Cleared, by, US, FDA, and, EMA",
"snippet": "ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage,...",
"url": "https://www.manilatimes.net/2025/12/05/tmt-newswire/globenewswire/ascentage-pharma-announces-global-registrational-phase-iii-study-of-olverembatinib-in-first-line-treatment-of-ph-all-cleared-by-us-fda-and-ema/2237587",
"image_url": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/05/855586.png",
"language": "en",
"published_at": "2025-12-05T00:17:44.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.500444,
"sentiment_score": 0.6908,
"highlights": [
{
"highlight": "Leveraging its robust R&D capabilities, [+325 characters]",
"sentiment": 0.6908,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ASPHF",
"name": "Ascentage Pharma Group International",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 46.46386,
"sentiment_score": -0.1027,
"highlights": [
{
"highlight": "ROCKVILLE, Md. and SUZHOU, China, Dec. 0[+348 characters]",
"sentiment": -0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "About Ascentage Pharma\n\n<em>Ascentage</e[+330 characters]",
"sentiment": -0.1027,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "6855.HK",
"name": "Ascentage Pharma Group International",
"exchange": null,
"exchange_long": null,
"country": "hk",
"type": "equity",
"industry": "Healthcare",
"match_score": 90.63722,
"sentiment_score": -0.1027,
"highlights": [
{
"highlight": "ROCKVILLE, Md. and SUZHOU, China, Dec. 0[+366 characters]",
"sentiment": -0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "About Ascentage Pharma\n\n<em>Ascentage</e[+348 characters]",
"sentiment": -0.1027,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "1801.HK",
"name": "Innovent Biologics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "hk",
"type": "equity",
"industry": "Healthcare",
"match_score": 18.526611,
"sentiment_score": 0.148,
"highlights": [
{
"highlight": "signing up with an email address, I ackn[+327 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Biologics</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "Healthcare",
"total_documents": 304,
"sentiment_avg": 0.23429087569278761
}
]
}
Other details
Entity count
- 11,338